Pilot Study of Rituximab, High Dose Cyclophosphamide, and GM-CSF Based Immunotherapy for Relapsed Hodgkin's Lymphoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs B cell lymphoma vaccine; Cyclophosphamide; Rituximab
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 26 Feb 2019 Biomarkers information updated
- 21 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Sep 2010 Planned end date changed from 1 Jul 2009 to 1 Oct 2011 as reported by ClinicalTrials.gov.